924 related articles for article (PubMed ID: 8402629)
21. Glutathione-mediated modulation of tetraplatin activity against sensitive and resistant tumor cells.
Kido Y; Khokhar AR; Siddik ZH
Biochem Pharmacol; 1994 Apr; 47(9):1635-42. PubMed ID: 8185678
[TBL] [Abstract][Full Text] [Related]
22. Antitumor activity and cross-resistance studies with Pt-ascorbato complexes.
Hrubisko M; Balázová E; Kiss F; Kovácová J; Ujházy V
Neoplasma; 1989; 36(6):651-7. PubMed ID: 2615869
[TBL] [Abstract][Full Text] [Related]
23. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
Knox RJ; Friedlos F; Lydall DA; Roberts JJ
Cancer Res; 1986 Apr; 46(4 Pt 2):1972-9. PubMed ID: 3512077
[TBL] [Abstract][Full Text] [Related]
24. Preparation of antitumor oxaliplatin/cisplatin docking dinuclear platinum complex.
Noji M; Kizu R; Takeda Y; Akiyama N; Yoshizaki I; Eriguchi M; Kidani Y
Biomed Pharmacother; 2005 Jun; 59(5):224-9. PubMed ID: 15919175
[TBL] [Abstract][Full Text] [Related]
25. Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers.
Pendyala L; Kidani Y; Perez R; Wilkes J; Bernacki RJ; Creaven PJ
Cancer Lett; 1995 Nov; 97(2):177-84. PubMed ID: 7497460
[TBL] [Abstract][Full Text] [Related]
26. Role of DNA replication in carrier-ligand-specific resistance to platinum compounds in L1210 cells.
Gibbons GR; Kaufmann WK; Chaney SG
Carcinogenesis; 1991 Dec; 12(12):2253-7. PubMed ID: 1747924
[TBL] [Abstract][Full Text] [Related]
27. A comparative study of the cytotoxicity and DNA-damaging effects of cis-(diammino)(1,1-cyclobutanedicarboxylato)-platinum(II) and cis-diamminedichloroplatinum(II) on L1210 cells.
Micetich KC; Barnes D; Erickson LC
Cancer Res; 1985 Sep; 45(9):4043-7. PubMed ID: 3896476
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the effectivity of two diaminocyclohexane Pt-complexes.
Balázová E; Hrubisko M; Ujházy V
Neoplasma; 1985; 32(5):537-42. PubMed ID: 4069288
[TBL] [Abstract][Full Text] [Related]
29. Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status.
Martelli L; Di Mario F; Botti P; Ragazzi E; Martelli M; Kelland L
Biochem Pharmacol; 2007 Jun; 74(1):20-7. PubMed ID: 17466278
[TBL] [Abstract][Full Text] [Related]
30. Characterization of chemosensitivity and resistance of human cancer cell lines to platinum(II) versus platinum(IV) anticancer agents.
Hamberger J; Liebeke M; Kaiser M; Bracht K; Olszewski U; Zeillinger R; Hamilton G; Braun D; Bednarski PJ
Anticancer Drugs; 2009 Aug; 20(7):559-72. PubMed ID: 19491657
[TBL] [Abstract][Full Text] [Related]
31. Differential antitumor activity and toxicity of isomeric 1,2-diaminocyclohexane platinum (II) complexes.
Siddik ZH; al-Baker S; Burditt TL; Khokhar AR
J Cancer Res Clin Oncol; 1993; 120(1-2):12-6. PubMed ID: 8270602
[TBL] [Abstract][Full Text] [Related]
32. Synthesis, structural characterization, and antitumor properties of a novel class of large-ring platinum(II) chelate complexes incorporating the cis-1,4-diaminocyclohexane ligand in a unique locked boat conformation.
Hoeschele JD; Showalter HD; Kraker AJ; Elliott WL; Roberts BJ; Kampf JW
J Med Chem; 1994 Aug; 37(17):2630-6. PubMed ID: 8064793
[TBL] [Abstract][Full Text] [Related]
33. Novel trans platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumours.
Goddard PM; Orr RM; Valenti MR; Barnard CF; Murrer BA; Kelland LR; Harrap KR
Anticancer Res; 1996; 16(1):33-8. PubMed ID: 8615631
[TBL] [Abstract][Full Text] [Related]
34. DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine, or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines.
Kasparkova J; Marini V; Najajreh Y; Gibson D; Brabec V
Biochemistry; 2003 May; 42(20):6321-32. PubMed ID: 12755637
[TBL] [Abstract][Full Text] [Related]
35. Cytotoxicity, cellular uptake, glutathione and DNA interactions of an antitumor large-ring Pt II chelate complex incorporating the cis-1,4-diaminocyclohexane carrier ligand.
Kasparkova J; Suchankova T; Halamikova A; Zerzankova L; Vrana O; Margiotta N; Natile G; Brabec V
Biochem Pharmacol; 2010 Feb; 79(4):552-64. PubMed ID: 19782655
[TBL] [Abstract][Full Text] [Related]
36. Mutagenicity, tumorigenicity, and electrophilic reactivity of the stereoisomeric platinum(II) complexes of 1,2-diaminocyclohexane.
Leopold WR; Batzinger RP; Miller EC; Miller JA; Earhart RH
Cancer Res; 1981 Nov; 41(11 Pt 1):4368-77. PubMed ID: 7030475
[TBL] [Abstract][Full Text] [Related]
37. Differential uptake of cis-diamminedichloroplatinum (II) by sensitive and resistant murine L1210 leukemia cells.
Waud WR
Cancer Res; 1987 Dec; 47(24 Pt 1):6549-55. PubMed ID: 3677093
[TBL] [Abstract][Full Text] [Related]
38. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates.
Kelland LR; Mistry P; Abel G; Loh SY; O'Neill CF; Murrer BA; Harrap KR
Cancer Res; 1992 Jul; 52(14):3857-64. PubMed ID: 1617660
[TBL] [Abstract][Full Text] [Related]
39. Cytotoxicity of platinum(IV) and platinum(II) complexes containing 1R,2R-cyclohexanediamine as a ligand.
Yamashita T; Hirose J; Noji M; Saito R; Tomida H; Kidani Y
Biol Pharm Bull; 1993 Oct; 16(10):1014-8. PubMed ID: 8287030
[TBL] [Abstract][Full Text] [Related]
40. Effect of diethyldithiocarbamate on cis-diamminedichloroplatinum(II)-induced cytotoxicity, DNA cross-linking, and gamma-glutamyl transpeptidase inhibition.
Bodenner DL; Dedon PC; Keng PC; Borch RF
Cancer Res; 1986 Jun; 46(6):2745-50. PubMed ID: 2870800
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
